Synonym
FY-609; HSR-609; FY 609; HSR 609; FY609; HSR609.
IUPAC/Chemical Name
3-(4-(8-fluorobenzo[6,7]oxepino[4,3-b]pyridin-11(5H)-ylidene)piperidin-1-yl)propanoic acid
InChi Key
VNMVYPKXIOJAGS-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H21FN2O3/c22-16-3-4-17-18(12-16)27-13-15-2-1-8-23-21(15)20(17)14-5-9-24(10-6-14)11-7-19(25)26/h1-4,8,12H,5-7,9-11,13H2,(H,25,26)
SMILES Code
O=C(O)CCN1CC/C(CC1)=C2C3=CC=C(F)C=C3OCC4=CC=CN=C4\2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
CAS No.
161522-25-4 (HSR-609 Free)
188199-97-5 (HSR-609 hydrate)
Preparing Stock Solutions
The following data is based on the
product
molecular weight
368.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Salmun LM. Antihistamines in late-phase clinical development for allergic disease. Expert Opin Investig Drugs. 2002 Feb;11(2):259-73. Review. PubMed PMID: 11829715.
2: Musoh K, Nakamura N, Nagai H. Effects of an amphoteric antiallergic agent, HSR-609, on antigen-induced late phase nasal eosinophilia in brown Norway rats. Pharmacology. 2000 Nov;61(4):230-7. PubMed PMID: 11093074.
3: Musoh K, Maeda Y, Tanaka H, Inagaki N, Nagai H. Effect of a novel anti-allergic agent, HSR-609, on antigen-induced airway hyperresponsiveness in mice. Pharmacology. 2000 Aug;61(2):70-7. PubMed PMID: 10940779.
4: Kakiuchi M, Ohashi T, Tanaka K, Ohara N, Kamiyama K, Morikawa K, Kato H. Central nervous system effects of the novel antiallergic agent HSR-609 and typical antiallergic agents using behavioral and electroencephalographic analyses in dogs. Nihon Shinkei Seishin Yakurigaku Zasshi. 1998 Oct;18(5):189-99. PubMed PMID: 10028490.
5: Kakiuchi M, Ohashi T, Tanaka K, Kamiyama K, Morikawa K, Kato H. Pharmacological studies on the novel antiallergic agent HSR-609: its effects on behavior in mice and electroencephalograms in rabbits. Jpn J Pharmacol. 1997 Sep;75(1):43-57. PubMed PMID: 9334885.
6: Kakiuchi M, Ohashi T, Musoh K, Kawamura K, Morikawa K, Kato H. Studies on the novel antiallergic agent HSR-609: its penetration into the central nervous system in mice and guinea pigs and its selectivity for the histamine H1-receptor. Jpn J Pharmacol. 1997 Apr;73(4):291-8. PubMed PMID: 9165365.
7: Hasegawa H, Takahara E, Yamada T, Nagata O. Sensitive analytical method for the novel H1-receptor antagonist HSR-609 in human plasma and urine by high-performance liquid chromatography with pre-column fluorescent derivatization. J Chromatogr B Biomed Appl. 1996 Dec 13;687(2):419-25. PubMed PMID: 9017466.
8: Iwasaki N, Ohashi T, Musoh K, Nishino H, Kado N, Yasuda S, Kato H, Ito Y. Amphoteric drugs. 3. Synthesis and antiallergic activity of 3-[(5,11-dihydro[1]benzoxepino[4,3-b]pyridin-11- ylidene)piperidino]propionic acid derivatives and related compounds. J Med Chem. 1995 Feb 3;38(3):496-507. PubMed PMID: 7853343.
